Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

Nature

Volumn 457, Issue 7225, 2009, Pages 87-91

  Liu, Jinyan ^a   O'Brien, Kara L ^a   Lynch, Diana M ^a   Simmons, Nathaniel L ^a   La Porte, Annalena ^a   Riggs, Ambryice M ^a   Abbink, Peter ^a   Coffey, Rory T ^a   Grandpre, Lauren E ^a   Seaman, Michael S ^a   Landucci, Gary ^b   Forthal, Donald N ^b   Montefiori, David C ^c   Carville, Angela ^a   Mansfield, Keith G ^a   Havenga, Menzo J ^d   Pau, Maria G ^e   Goudsmit, Jaap ^e   Barouch, Dan H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d TNO   (Netherlands)

^e CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; VACCINE;

ALLELE; CYTOLOGY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; PRIMATE; RECOMBINATION; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOGENICITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; THERAPY EFFECT; VIRUS LOAD;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; MACACA MULATTA; NEUTRALIZATION TESTS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRAL LOAD;

ADENOVIRIDAE; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 58149267963     PISSN: 00280836     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/nature07469     Document Type: Article

References (30)

1. Fauci, A. S. The release of new data from the HVTN 502 (STEP) HIV vaccine study. National Institutes of Health (NIH) News, November 7 (2007).
2. Fauci, A. S. 25 years of HIV. Nature 453, 289-290 (2008).
3. Casimiro, D. R. et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79, 15547-15555 (2005).
4. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
5. Shiver, J. W. & Emini, E. A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
6. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312, 1530-1533 (2006).
7. Catanzaro, A. T. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194, 1638-1649 (2006).
8. Priddy, F. H. et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46, 1769-1781 (2008).
9. Barouch, D. H. et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172, 6290-6297 (2004).
10. Abbink, P. et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654-4663 (2007).
11. Liu, J. et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82, 4844-4852 (2008).
12. Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77, 8263-8271 (2003).
13. mac239 replication. J. Virol. 77, 2736-2740 (2003).
14. mac-induced immunodeficiency. J. Virol. 76, 292-302 (2002).
15. Zhang, Z. Q. et al. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J. Virol. 76, 12845-12854 (2002).
16. Yant, L. J. et al. The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 80, 5074-5077 (2006).
17. Santra, S. et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79, 6516-6522 (2005).
18. + T cells. Blood 107, 4781-4789 (2006).
19. H1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature Med. 13, 843-850 (2007).
20. + effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 204, 2171-2185 (2007).
21. Pitcher, C. J. et al. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168, 29-43 (2002).
22. Montefiori, D. Evaluating Neutralizing Antibodies Against HIV, SIV and SHIV in Luciferase Reporter Gene Assays (eds Coligan, J. E et al.) (Current Protocols in Immunology, John Wiley & Sons, 2004).
23. Forthal, D. N., Landucci, G. & Daar, E. S. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75, 6953-6961 (2001).
24. + T cells in lymphoid tissues during simian immunodeficiency virus infection. J. Virol. 74, 11001-11007 (2000).
25. + lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 82, 5618-5630 (2008).
26. + T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998).
27. + T cells. Nature 434, 1148-1152 (2005).
28. + T cells in multiple tissues during acute SIV infection. Nature 434, 1093-1097 (2005).
29. Wilson, N. A. et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80, 5875-5885 (2006).
30. + T-cell responses to different HIV proteins have discordant associations with viral load. Nature Med. 13, 46-53 (2007).